Before CRISPR/Cas9 became the dominant genome-editing platform, transcription activator-like effector nucleases (TALENs) and zinc finger nucleases (ZFNs) were the primary tools for targeted genome modification. Both use a modular DNA-binding domain fused to the endonuclease domain of FokI.
Zinc Finger Nucleases
A ZFN consists of 3–6 zinc finger modules, each recognizing 3–4 bp of DNA. Two ZFN monomers bind adjacent sites with a 5–7 bp spacer between them. FokI must dimerize to cut DNA, so only the paired ZFN–FokI complex creates a double-strand break.
Zinc finger modules are not truly modular: the specificity of each finger is influenced by its neighbors, making ZFN design difficult. Most ZFNs must be selected from large combinatorial libraries or engineered using proprietary platforms (Sangamo Biosciences). This complexity limited ZFN adoption despite their success in early therapeutic trials (SB-728-T for HIV, phase 1).
TALENs
TALENs use the DNA-binding domain of transcription activator-like (TAL) effectors from Xanthomonas bacteria. Each TAL repeat recognizes a single nucleotide through two hypervariable amino acid residues (the repeat-variable diresidue, or RVD). The code is simple and predictable:
- HD → C
- NG → T
- NI → A
- NN → G or A
- NH → G (higher specificity)
A typical TALEN array has 12–20 repeats targeting a 12–20 bp sequence. Like ZFNs, TALENs are used as a pair flanking a 12–20 bp spacer, with FokI domains dimerizing across the spacer.
TALEN assembly is modular, each repeat is a standardized part, and methods such as Golden Gate cloning (MoClo, Golden TALEN, FLASH) allow assembly of TALEN arrays from pre-made repeat modules.
Comparison with CRISPR/Cas9
| Feature | ZFNs | TALENs | CRISPR/Cas9 |
|---|---|---|---|
| Design | Difficult | Moderate | Easy |
| Target length | 18–36 bp | 24–40 bp | 20 bp + PAM |
| Off-target effects | Low | Very low | Variable |
| Multiplexing | Hard | Hard | Easy |
| Cost | High | Medium | Low |
| Delivery size | Small (1 kb) | Large (3 kb) | Medium (4 kb for Cas9) |
TALENs offer the lowest off-target rate of all three platforms because the target site is longer and each TAL repeat binds a single nucleotide. However, the large size of each TALEN monomer (≈3 kb) makes delivery in AAV vectors challenging. ZFNs are small enough for AAV packaging but are difficult to engineer in-house.
Applications
ZFNs and TALENs are still used in applications where off-target cutting must be absolutely minimized (e.g., therapeutic editing in stem cells) or where CRISPR PAM requirements are restrictive. TALENs have no PAM requirement and can target any sequence, including sequences lacking an NGG PAM.
